Applied Genetic Technologies Corp.
Report 12-month data for Phase 1/2 dose groups 5 and 6
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“2021: 2Q: 12-month data for Phase 1/2 dose groups 5 and 6”
What we found
Evidence strength A What the grades mean
The company reported the 12-month data for the high dose groups (groups 5 and 6) in July 2021, which is after the second quarter 2021 deadline.
-
A Applied Genetic Technologies Corp. 10-K filed 2021-09-23
“in July 2021, reported full 12-month data showing a 50% response rate in the high dose groups.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- 12-month clinical trial data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Applied Genetic Technologies Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C273636-022720 · Corrections policy